2022 ASCO前瞻 | 結直腸癌領域重磅研究一覽

一年一度的全球腫瘤界盛會——美國臨床腫瘤學會（ASCO）年會將于當地時間6月3日-7日召開。醫脈通對結直腸癌領域的部分重磅研究進展進行了梳理。一起來看下吧！

全體大會

標題：Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.

報告人：Takayuki Yoshino, PhD

單位：National Cancer Center Hospital East

口頭報告

標題：Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial.

報告人：胡華斌

單位：中山大學附屬第六醫院

標題：Noninferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 (T2T3sN0M0) undergoing neoadjuvant treatment and local excision (TEM) versus total mesorectal excision (TME): Preoperative, surgical, and pathological outcomes—The TAUTEM-study.

報告人：Xavier Serra-Aracil

單位：Corporacion Sanitaria Parc Tauli

標題：STAR-TREC phase II: Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?

報告人：Simon Parkinson Bach, MD FRCS

單位：University of Birmingham

標題：Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.

報告人：Antonio Avallone, MD

單位：Istituto Nazionale Tumori Fondazione G. Pascale

標題：STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.

報告人：Benoist Chibaudel, MD

單位：Department of Medical Oncology, Franco-British Institute

標題：Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO.

報告人：Chiara Cremolini, MD, PhD

單位：Department of Translational Research and New Technologies in Medicine and Surgery-Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana

標題：FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or RAS/BRAFV600E-mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.

報告人：Cornelis J. A. Punt, MD, PhD

單位：University Medical Center Utrecht

標題：Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study.

報告人：Stefano Kim, MD

單位：Bourgogne-Franche Comté University, Department of Medical Oncology, Besan?on University Hospital

標題：Phase II study of nivolumab in combination with FOLFOXIRI/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018).

報告人：Angela Damato, MD

單位：Medical Oncology Unit, Azienda USL-IRCCS Reggio Emilia

標題：Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.

報告人：Michael J. Overman, MD

單位：University of Texas MD Anderson Cancer Center and SWOG

標題：Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.

報告人：Yara L. Verschoor, MD

單位：Netherlands Cancer Institute

標題：A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results.

報告人：Stefano Tamberi, MD, PhD

單位：UOC Oncologia Ravenna, AUSL Romagna

壁報展示

標題：A phase 2 trial of sintilimab (IBI 308) in combination with CAPEOX and bevacizumab (BBCAPX) as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.

報告人：房雪峰

單位：浙江大學醫學院附屬第二醫院腫瘤內科，腫瘤防治教育部重點實驗室

標題：Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study.

報告人：Xiaojing Xu

單位：復旦大學附屬中山醫院腫瘤內科

標題：CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.

報告人：徐建明

單位：中國人民解放軍總醫院第五醫學中心

標題：Camrelizumab plus famitinib in patients with metastatic colorectal cancer: Results from an open-label, multicenter phase II basket study.

報告人：劉天舒

單位：復旦大學附屬中山醫院腫瘤內科

標題：Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.

報告人：Zhichao Jiang

單位：中國醫學科學院北京協和醫學院腫瘤醫院腫瘤研究所（國家癌癥中心）

標題：PKUCH 04 trial: Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for pMMR/MSS locally advanced middle to low rectal cancer.

報告人：武愛文

單位：北京大學腫瘤醫院